冠状动脉内血栓形成在心肌梗塞的发生机制上起着重要作用。目前使用链激酶或尿激酶治疗急性心肌梗塞,虽有一定效果,但由于这些药物不加选择的作用于循环中的和已与纤维蛋白结合的纤溶酶原,故可导致广泛纤溶。使用组织型纤溶酶原激活剂(t-PA),很少有这种危险。因而,从t-PA的发现和提纯,在不到十年时间,就得到迅速的发展。表现在:①t-PA的分离和纯化;②人t-PA基因的无性系培养和表达;③纯化t-PA对实验性冠状动脉血栓形成动物疗效的观察;①t-PA在急性心肌梗塞病人中溶栓作用的评价.③血浆t-PA的检测方 Coronary thrombosis plays an important role in the pathogenesis of myocardial infarction. The current use of streptokinase or urokinase in the treatment of acute myocardial infarction, although with some effect, leads to extensive fibrinolysis due to the indiscriminate effect of these drugs on circulating fibrinolytic plasminogen. With tissue-type plasminogen activator (t-PA), there is very little danger. Thus, the discovery and purification of t-PA have been rapidly developed in less than a decade. The results were as follows: ①Isolation and purification of t-PA; ②Culture and expression of human t-PA gene; ③Treatment effect of purified t-PA on experimental coronary thrombosis animal; ①t-PA in acute myocardial infarction patients Evaluation of thrombolytic effect .③ detection of plasma t-PA side